1-Formyloxyethyl 2-methylpropanoate | 41448-50-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-Formyloxyethyl 2-methylpropanoate
• CAS: 41448-50-4
• 化学式: C₇H₁₂O₄
• 分子量: 160.17
• InChiKey: WXUUGZYRUMEFFK-UHFFFAOYSA-N

物化性质

• 沸点：
  187.8±23.0 °C(Predicted)
• 密度：
  1.053±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  甲酸 、 异丁酸酐 、 乙醛 生成 1-Formyloxyethyl 2-methylpropanoate
  参考文献：
  名称：

  Mixed Acylals; Synthesis of Alkylidene Carboxylate Formates

  摘要：

  DOI：

  10.1055/s-1973-22151

文献信息

• [EN] NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS DE 1,3-OXAZOLIDINE ET UTILISATION DE CES DERNIERS COMME INHIBITEURS DE LA RÉNINE
  申请人：NOVADEX PHARMACEUTICALS AB

  公开号：WO2011056126A1

  公开（公告）日：2011-05-12

  The present invention relates to certain novel 1,3-oxazolidine compounds of formula (I), to processes for making such compounds and to their utility as renin inhibitors or prodrugs of renin inhibitors.

  本发明涉及某些新颖的1,3-噁唑烷化合物（I）的公式，以及制备这类化合物的方法，以及它们作为肾素抑制剂或肾素抑制剂的前药的用途。
• Benzimidazole derivatives, their production and use
  申请人：Naka Takehiko

  公开号：US20070259932A1

  公开（公告）日：2007-11-08

  Benzimidazole derivatives of the formula (I): wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R′ group; R 1 is hydrogen or an optionally substituted hydrocarbon residue; R 2 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; R′ is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or convertible to an anion; Y is —O—, —S(O) m — or —N(R 4 )— wherein m is an integer of 0, 1 or 2 and R 4 is hydrogen or an optionally substituted alkyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.

  公式（I）中的苯并咪唑衍生物： 其中环A是苯环，除了R′基之外，还可以选择性地含有取代基；R1是氢或可选择性取代的碳氢基；R2是能够形成负离子或可转化为负离子的基团；X是直接键或具有原子长度为两个或更少的间隔物，在苯基团和苯基团之间；R′是羧基，其酯，其酰胺或能够形成负离子或可转化为负离子的基团；Y是-O-，-S（O）m-或-N（R4）-，其中m是0、1或2的整数，R4是氢或可选择性取代的烷基；n是1或2的整数；以及其药物学上可接受的盐，具有强大的血管紧张素II拮抗活性和降压活性，因此可用作治疗循环系统疾病，如高血压疾病、心脏疾病（例如心脏肥大、心力衰竭、心肌梗塞等）、中风、脑卒中、肾炎等的治疗剂。
• Sustained-release medicines
  申请人：——

  公开号：US20040219208A1

  公开（公告）日：2004-11-04

  Sustained-release medicines comprising (A) an angiotensin II antagonist combined with (B) one or more drugs selected from among remedies for hypertension, hypoglycemics, remedies for hyperlipemia, antithromboties, remedies for menopause and anticancer drugs. Using these medicines, remarkably excellent effects can be achieved compared with the case of using each active ingredient alone, which makes it possible to lessen the administration dose and relieve side effects.

  持续缓释药物包括（A）一种血管紧张素II受体拮抗剂与（B）一种或多种从治疗高血压、降糖药、降脂药、抗血栓药、更年期药和抗癌药中选择的药物组合。使用这些药物，可以比单独使用每种活性成分时获得显着优异的效果，从而可以减少给药剂量并缓解副作用。
• Cycloalkyl-Substituted Imidazole Derivative
  申请人：Nagata Tsutomu

  公开号：US20130022587A1

  公开（公告）日：2013-01-24

  A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R 1 , R 2 , and R 3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R 4 represents a hydrogen atom or a prodrug group; and Y represents —CH 2 —CHR 5 —CH 2 —NHR 6 (wherein R 5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R 6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

  以下是通式（I）所代表的化合物或其药学上可接受的盐，其中A代表一个C3到C12的环烷基，该环烷基可以被一个到三个选自氟基、羟基、C1到C6烷基等的基团所取代；R1、R2和R3各自独立地代表氢原子、氟基或C1到C6烷基；R4代表氢原子或前药基团；Y代表—CH2—CHR5— —NHR6（其中R5代表氢原子、C1到C6烷基或C1到C6烷氧基，R6代表氢原子或前药基团）等，具有极好的TAFIa抑制活性，是治疗心肌梗死、心绞痛、急性冠状动脉综合征、脑梗死、深静脉血栓形成、肺栓塞等疾病的治疗药物。
• NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS
  申请人：Sun Piaoyang

  公开号：US20130005730A1

  公开（公告）日：2013-01-03

  The present invention relates to certain novel 1,3-oxazolidine compounds of formula (I), to processes for making such compounds and to their utility as renin inhibitors or prodrugs of renin inhibitors.

  本发明涉及一些新型1,3-噁唑啉化合物(I)的公式，制备这些化合物的方法以及它们作为肾素抑制剂或肾素抑制剂的前药的用途。